CoChat

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration

Open access
Strunz, Tobias, Pöllmann, Michael, Gamulescu, Maria-Andreea, Tamm, Svenja, Weber, Bernhard H. F. · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) has been FDA-approved in 2004, and since then has helped tens of thousands of patients worldwide to preserve vision. Still, treatment responses vary widely, emphasizing the need for genetic biomarkers to robustly separate responders from non-responders. Here, we report the findings of an observational study compromising 179 treatment-naïve nAMD patients and their reaction to treatment after three monthly doses of anti-VEGF antibodies. We show that established criteria of treatment response such as visual acuity and central retinal thickness successfully divides our cohort into 128 responders and 51 non-responders. Nevertheless, retinal thickness around the fovea revealed significant reaction to treatment even in the formally categorized non-responders. To elucidate genetic effects underlying our criteria, we conducted an undirected genome-wide association study followed by a directed replication study of 30 previously reported genetic variants. Remarkably, both approaches failed to result in significant findings, suggesting study-specific effects were confounding the present and previous discovery studies. Of note, all studies so far are greatly underpowered, hampering interpretation of genetic findings. In consequence, we highlight the need for an extensive phenotyping study with sample sizes exceeding at least 15,000 to reliably assess anti-VEGF treatment responses in nAMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23116094

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Exemplary optical coherence tomography (OCT) images of nAMD patients and their categorization according to treatment responses. Shown are the OCT images of four patients (A–D) before (baseline) and after treatment (treated). Individuals in (A,B) were assigned to the responder group, while probands in (C,D) were more complex in their response to treatment. The individual in (C) was categorized as a responder due to morphological improvements (101 µm decrease in central retinal thickness) and a strong improvement of visual acuity (gain of 0.3 logMAR), although a dry retina was not achieved during the treatment period. The patient in (D) was not responsive to the treatment and was assigned as a non-responder.
Figure 1 Exemplary optical coherence tomography (OCT) images of nAMD patients and their categorization according to treatment responses. Shown are the OCT images of four patients (A–D) before (baseline) and after treatment (treated). Individuals in (A,B) were assigned to the responder group, while probands in (C,D) were more complex in their response to treatment. The individual in (C) was categorized as a responder due to morphological improvements (101 µm decrease in central retinal thickness) and a strong improvement of visual acuity (gain of 0.3 logMAR), although a dry retina was not achieved during the treatment period. The patient in (D) was not responsive to the treatment and was assigned as a non-responder.CC BY · PubMed Central
Figure 2 Clinical characteristics of non-responders and responders. The 179 study participants were grouped one month after three monthly anti-VEGF nAMD treatments in non-responders or responders according to the presence of retinal fluid or the strong improvement of clinical markers like central retinal thickness (decrease of > 200µm) or visual acuity (gain of >10 letters, logMAR < −0.2). This resulted in 128 responders and 51 non-responders. Shown are the measurements of visual acuity (A), central retinal thickness (B) and thickest retinal thickness (C) at baseline and after treatment. A pairwise Wilcoxon test, adjusted for multiple testing, was performed to determine significant differences between the two groups. Adjusted p-value thresholds: ns ≥0.05, * <0.05, ** <0.01, and *** <0.001. In (A), a single outlier of the responder group with visual acuity of 2.2 logMAR at baseline is not depicted to facilitate optimal scaling of the data.
Figure 2 Clinical characteristics of non-responders and responders. The 179 study participants were grouped one month after three monthly anti-VEGF nAMD treatments in non-responders or responders according to the presence of retinal fluid or the strong improvement of clinical markers like central retinal thickness (decrease of > 200µm) or visual acuity (gain of >10 letters, logMAR < −0.2). This resulted in 128 responders and 51 non-responders. Shown are the measurements of visual acuity (A), central retinal thickness (B) and thickest retinal thickness (C) at baseline and after treatment. A pairwise Wilcoxon test, adjusted for multiple testing, was performed to determine significant differences between the two groups. Adjusted p-value thresholds: ns ≥0.05, * <0.05, ** <0.01, and *** <0.001. In (A), a single outlier of the responder group with visual acuity of 2.2 logMAR at baseline is not depicted to facilitate optimal scaling of the data.CC BY · PubMed Central
Figure 3 Genome-wide association study of anti-VEGF nAMD treatment response. We performed a logistic regression model to test the association of genetic variants with anti-VEGF nAMD treatment response. The study included 128 responders and 51 non-responders. (A) A quantile–quantile (QQ) plot of the results compares observed p-values with those expected under the null hypothesis of no association. (B) The Manhattan plot shows the -log10 p-values and positions of 6,908,005 variants. The blue line indicates the threshold for genome-wide significance at 5 × 10−8.
Figure 3 Genome-wide association study of anti-VEGF nAMD treatment response. We performed a logistic regression model to test the association of genetic variants with anti-VEGF nAMD treatment response. The study included 128 responders and 51 non-responders. (A) A quantile–quantile (QQ) plot of the results compares observed p-values with those expected under the null hypothesis of no association. (B) The Manhattan plot shows the -log10 p-values and positions of 6,908,005 variants. The blue line indicates the threshold for genome-wide significance at 5 × 10−8.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. 2017, ggplot2-Elegant Graphics for Data Analysis (2nd Edition), J. Stat. Softw., 77, 1
  2. (2021, December 09). Available online: https://pubmed.ncbi.nlm.nih.gov/.

Cited by

See all 11

Metadata

Authors
Strunz, T., Pöllmann, M., Gamulescu, M.-A., Tamm, S., & Weber, B. H. F.
Affiliations
  • University of Regensburg (DE)
  • University Hospital Regensburg (DE)
Corresponding author
  • Tamm, Svenja
  • Weber, Bernhard H. F.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-05-29
Volume
23
Issue
11
Pages
6094
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4281718306
Cited by
10
References
38
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 3
FWCI
1.79
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
Funders
Institute of Human Genetics Regensburg, Germany (TG77)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
neovascular age-related macular degeneration, anti-VEGF therapy, treatment response, genetic biomarkers, genome-wide association study, retinal thickness, visual acuity, genetic variants
MeSH terms
Ranibizumab, Antibodies, Monoclonal, Humans, Macular Degeneration, Treatment Outcome, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Genome-Wide Association Study, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.3390/ijms23116094
The paper
Strunz, T., Pöllmann, M., Gamulescu, M.-A., Tamm, S., & Weber, B. H. F. (2022). Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23116094

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.